Celecoxib/olmesartan - Marina Biotech

Drug Profile

Celecoxib/olmesartan - Marina Biotech

Alternative Names: IT-103

Latest Information Update: 18 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator IthenaPharma
  • Developer Marina Biotech
  • Class Analgesics; Antihypertensives; Antirheumatics; Imidazoles; Nonsteroidal anti-inflammatories; Pyrazoles; Small molecules
  • Mechanism of Action Angiotensin type 1 receptor antagonists; Cyclo-oxygenase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Inflammation
  • Preclinical Arthritis; Cancer; Hypertension; Pain

Most Recent Events

  • 08 Sep 2017 Pharmacodynamics data from a preclinical trial in Cancer presented at the 42nd European Society for Medical Oncology (ESMO-2017)
  • 29 Mar 2017 Preclinical trials in Arthritis in USA prior to March 2017 (unspecified route)
  • 29 Mar 2017 Preclinical trials in Hypertension in USA prior to March 2017 (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top